Minocycline, a microglial inhibitor, blocks spinal CCL2-induced heat hyperalgesia and augmentation of glutamatergic transmission in substantia gelatinosa neurons by Chung-Yu Huang et al.
JOURNAL OF 
NEUROINFLAMMATION
Huang et al. Journal of Neuroinflammation 2014, 11:7
http://www.jneuroinflammation.com/content/11/1/7RESEARCH Open AccessMinocycline, a microglial inhibitor, blocks spinal
CCL2-induced heat hyperalgesia and augmentation
of glutamatergic transmission in substantia
gelatinosa neurons
Chung-Yu Huang1†, Ying-Ling Chen2†, Allen H Li3, Juu-Chin Lu1 and Hung-Li Wang1,4,5*Abstract
Background: Several lines of evidence suggest that CCL2 could initiate the hyperalgesia of neuropathic pain by
causing central sensitization of spinal dorsal horn neurons and facilitating nociceptive transmission in the spinal
dorsal horn. The cellular and molecular mechanisms by which CCL2 enhances spinal pain transmission and causes
hyperalgesia remain unknown. The substantia gelatinosa (lamina II) of the spinal dorsal horn plays a critical role in
nociceptive transmission. An activated spinal microglia, which is believed to release pro-inflammatory cytokines
including TNF-α, plays an important role in the development of neuropathic pain, and CCL2 is a key mediator for
spinal microglia activation. In the present study, we tested the hypothesis that spinal CCL2 causes the central
sensitization of substantia gelatinosa neurons and enhances spinal nociceptive transmission by activating the spinal
microglia and augmenting glutamatergic transmission in lamina II neurons.
Methods: CCL2 was intrathecally administered to 2-month-old male rats. An intrathecal injection of CCL2 induced
heat hyperalgesia, which was assessed using the hot plate test. Whole-cell voltage-clamp recordings substantia
gelatinosa neurons in spinal cord slices were performed to record glutamatergic excitatory postsynaptic currents
(EPSCs) and GABAergic inhibitory postsynaptic currents (IPSCs).
Results: The hot plate test showed that 1 day after the intrathecal injection of CCL2 (1 μg), the latency of hind-paw
withdrawal caused by a heat stimulus was significantly reduced in rats. One day after the intrathecal administration
of CCL2, the amplitude of the evoked glutamatergic EPSCs and the frequency of spontaneous glutamatergic
miniature EPSCs (mEPSCs) were significantly increased in outer lamina II neurons. Intrathecal co-injection of
minocycline, a specific inhibitor of microglial activation, and CCL2 blocked the CCL2-induced reduction in the
latency of hind-paw withdrawal and thermal hyperalgesia. Following intrathecal co-administration of CCL2 and
minocycline, CCL2 failed to increase the frequency of glutamatergic mEPSCs and failed to promote glutamine
release in lamina II neurons. Intrathecal co-injection of WP9QY, a selective TNF-α antagonist, and CCL2 completely
inhibited CCL2-induced heat hyperalgesia and inhibited the increase in the frequency of glutamatergic mEPSCs in
substantia gelatinosa neurons.
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Conclusion: In summary, our results suggest that an intrathecal injection of CCL2 causes thermal hyperalgesia by
augmenting the excitatory glutamatergic transmission in substantia gelatinosa neurons through a presynaptic
mechanism and facilitating nociceptive transmission in the spinal dorsal horn. Further studies show that intrathecal
co-administration of minocycline, a specific inhibitor of microglial activation, or WP9QY, a selective TNF-α antagonist,
completely inhibited CCL2 potentiation of glutamatergic transmission in substantia gelatinosa neurons and
CCL2-induced heat hyperalgesia. The results of the present study suggest that peripheral nerve injury-induced
upregulation of the spinal CCL2 level causes the central sensitization of substantia gelatinosa neurons by activating
spinal microglia and that TNF-α mediates CCL2-induced thermal hyperalgesia and augmentation of glutamatergic
transmission in lamina II neurons.
Keywords: CC chemokine ligand 2, Heat hyperalgesia, Substantia gelatinosa neurons, Glutamatergic transmission,
Microglia, Tumor necrosis factor-αBackground
Several lines of evidence indicate that CC chemokine lig-
and 2 (CCL2)/monocyte chemoattractant protein-1 re-
leased during peripheral nerve injury is involved in
mediating the hyperalgesia of neuropathic pain in the
spinal dorsal horn [1-7]. CCL2 is constitutively present
in dorsal root ganglion (DRG) neurons with small or
medium diameters and their processes in the dorsal
horn of the spinal cord (DHSC), in which it is co-
localized with transient receptor potential vanilloid
receptor 1 (TRPV1) and the pain-related peptide, sub-
stance P (SP), or calcitonin gene-related peptide (CGRP)
[2]. The presence of CCL2 in primary nociceptive affer-
ent fibers and in secretory vesicles in the DHSC suggests
that CCL2 is transported and subsequently released
from the central terminals of nociceptive DRG neurons
[2,5,8]. In accord with this hypothesis, high potassium or
capsaicin levels evoke a calcium-dependent secretion of
CCL2 from DHSC explants of rats [2,5]. The expression
level of CCL2 or its receptor CCR2 in the spinal dorsal
horn is upregulated in animal models of neuropathic
pain [1,3,4,9,10]. Furthermore, a higher level of CCL2 re-
leased from the DHSC has been observed in a rat model
of neuropathic pain [5]. When administered intrathecally
into naive rats, CCL2 induces thermal hyperalgesia
[2,11]. In addition, an intrathecal administration of anti-
CCL2 antibodies inhibits neuropathic pain behavior [12].
These findings suggest that CCL2 could initiate the
hyperalgesia of neuropathic pain by causing central
sensitization of spinal dorsal horn neurons and enhan-
cing nociceptive transmission in the spinal dorsal horn.
Further study is required to investigate the cellular and
molecular mechanisms by which CCL2 facilitates pain
transmission in the spinal dorsal horn.
Finely myelinated Aδ and unmyelinated C glutamater-
gic afferent fibers that convey predominantly nociceptive
information terminate within the substantia gelatinosa
(lamina II) of spinal dorsal horn [13-17]. Pain informa-
tion carried by small primary afferent fibers is processedand integrated by lamina II nociceptive neurons. There-
fore, the substantia gelatinosa functions as the first relay
station in the nociceptive pathway and plays a critical
role in nociceptive transmission [16,17]. The excitability
and activity of lamina II neurons is mainly regulated by
glutamate released from primary nociceptive afferents
[14,16,17]. Under pathological conditions, augmented
glutamatergic transmission and resulting enhanced ex-
citability of substantia gelatinosa neurons is expected to
cause the hyperalgesia [18,19]. Immunohistochemical
staining of CCL2 is most intense within the substantia
gelatinosa, and CCL2 also co-localizes with substance P
and CGRP-immunoreactive axon terminals in the outer
portion of lamina II [2]. Following peripheral nerve
injury, central axon terminals of DRG neurons and acti-
vated astrocytes in the spinal dorsal horn release CCL2
[3,5]. Considering the physiological importance of lam-
ina II neurons in processing pain sensation, it is very
likely that during neuropathic pain, upregulated CCL2 in
superficial dorsal horn induces the hyperalgesia by aug-
menting excitatory glutamatergic transmission of sub-
stantia gelatinosa neurons and causing the central
sensitization of lamina II neurons.
Finely myelinated Aδ and unmyelinated C glutamater-
gic afferent fibers that convey predominantly nociceptive
information terminate within the substantia gelatinosa
(lamina II) of the spinal dorsal horn [13-17]. Pain infor-
mation carried by small primary afferent fibers is proc-
essed and integrated by lamina II nociceptive neurons.
Therefore, the substantia gelatinosa functions as the first
relay station in the nociceptive pathway and plays a crit-
ical role in nociceptive transmission [16,17]. The excit-
ability and activity of lamina II neurons is mainly
regulated by glutamate released from primary nocicep-
tive afferents [14,16,17]. Under pathological conditions,
augmented glutamatergic transmission and the resulting
enhanced excitability of substantia gelatinosa neurons
are thought to cause hyperalgesia [18,19]. Immunohisto-
chemical staining of CCL2 is most intense within the
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substance P and CGRP-immunoreactive axon terminals
in the outer portion of lamina II [2]. Following periph-
eral nerve injury, the central axon terminals of DRG
neurons and activated astrocytes in the spinal dorsal
horn release CCL2 [3,5]. Considering the physiological
importance of lamina II neurons in processing the sensa-
tion of pain, it is very likely that during neuropathic pain,
upregulated CCL2 in the superficial dorsal horn induces
hyperalgesia by augmenting the excitatory glutamatergic
transmission in substantia gelatinosa neurons and causing
the central sensitization of lamina II neurons.
Several lines of evidence indicate that the spinal microglia
plays an important role in the development of chronic pain
[7,20-25]. Microglia in the spinal dorsal horn are converted
from their resting shape to an activated shape after nerve
injury or peripheral inflammation [20-22]. Inhibition of
microglial activation attenuates the development of neuro-
pathic pain [26]. Activated microglia produce and release
various pro-inflammatory cytokines including tumor necro-
sis factor-α (TNF-α) [27-29]. Pro-inflammatory cytokines
released by activated microglia could induce the central
sensitization of substantia gelatinosa neurons by altering
the excitatory or inhibitory synaptic transmission and cause
hyperalgesia [30,31].
CCL2 is a key mediator for spinal microglia activation
during neuropathic pain [7,12,23,24,29]. CCR2 is expressed
in the spinal microglia [9]. When administered intra-
thecally, CCL2 causes microglial activation in the spinal
dorsal horn of naive animals but not in CCR2-deficient
mice [12,32]. Furthermore, a spinal injection of CCL2-
neutralizing antibodies blocked microglial activation in-
duced by nerve injury in the spinal dorsal horn [12,32].
Therefore, it is very likely that following peripheral nerve
injury, an elevated CCL2 level within the spinal dorsal horn
could cause the central sensitization of substantia gelatinosa
neurons and enhance spinal nociceptive transmission by
activating spinal microglia cells. In accord with this hy-
pothesis, the present study provides evidence that mino-
cycline, an inhibitor of microglial activation, blocks heat
hyperalgesia induced by intrathecal injection of CCL2
and augmentation of glutamatergic transmission in sub-
stantia gelatinosa neurons. Our results also suggest that
TNF-α mediates CCL2-induced thermal hyperalgesia and




Male Sprague–Dawley (SD) rats (BioLASCo Taiwan Co,
Ltd), 2 months old, were used in the current study. The
animals were housed under a 12 h light/dark cycle in a
temperature-controlled room with ad libitum access to
food and water. The animals were handled accordingto protocols approved by the Animal Care and Use
Committee of Chang Gung University.
Drugs
Recombinant rat CCL2 was obtained from R&D Systems
(Minneapolis, MN, USA). Minocycline was purchased from
Sigma (St Louis, MO, USA). BMS CCR2 22, picrotoxin,
strychnine, tetrodotoxin, 2-amino-5-phosphonovale-
rate (APV) and 6-cyano-7-nitroquinoxaline-2,3-dione
(CNQX) were obtained from Tocris Bioscience (Bristol,
UK). WP9QY was purchased from Santa Cruz (Dallas, TX,
USA).
Intrathecal administration of CCL2
As in a previous study [11], 2-month-old male Sprague–
Dawley rats were intrathecally administered with CCL2.
Briefly, the rats were lightly anesthetized with isoflurane.
Then, 1 μg of CCL2 (R & D Systems) dissolved in 10 μl
PBS containing 0.1% BSA and protease inhibitor cocktail
was intrathecally injected into the rats through an acute
lumbar puncture between L4 and L5 using a 25-gauge
stainless steel needle connected to a microsyringe. As a
control, 10 μl of PBS containing 0.1% BSA and protease
inhibitor cocktail was intrathecally administered to rats.
Hot plate test for CCL2-induced heat hyperalgesia
As in a previous study [2], CCL2-induced thermal hyper-
algesia was assessed using the hot plate test. Briefly, the
animals were acclimatized to manipulations and behav-
ioral apparatus (Model 7280 Hot Plate, Ugo Basile Bio-
logical Research Apparatus) for 2 days. The animals
were then placed on a heated plate (50°C). The applica-
tion of thermal stimuli to an animal caused the with-
drawal of the hind paws, observed as licking of the hind
paws. The latency value of hind-paw withdrawal due to
a heat stimulus was recorded. For each experiment for
measuring withdrawal latency, four latency measure-
ments were taken at 10 min intervals to obtain a mean
latency value.
Whole-cell patch-clamp recordings in spinal cord slices
Whole-cell patch-clamp recordings of substantia gelati-
nosa neurons in a spinal cord slice were performed as
for our previous studies [33,34]. Briefly, the rats were
terminally anesthetized with sodium pentobarbital. The
lumbar region of the spinal cord was removed and 350-
μm-thick transverse slices were prepared using a vibra-
tome slicer (VT 1000S, Leica) in an ice-cold extracellular
solution containing: NaCl 80 mM, sucrose 75 mM, KCl
2.5 mM, MgCl2 3.5 mM, NaH2PO4 1.25 mM, CaCl2 0.5
mM, NaHCO3 26 mM, ascorbic acid 1.5 mM, sodium
pyruvate 3 mM and kynurenic acid 0.01 mM. Before be-
ing used for patch-clamp recordings, the spinal cord
slices were transferred to a holding chamber where they
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containing: NaCl 120 mM, KCl 2.4 mM, MgCl2 2 mM,
NaHCO3 26 mM, CaCl2 2 mM, NaH2PO4 1.25 mM and
glucose 15 mM. The ACSF was gassed with 95% O2/5%
CO2 for 1 hour.
Following the recovery period, a spinal cord slice was
transferred to a recording chamber mounted on the
stage of an upright microscope (Axioskop, Zeiss) and
superfused continuously with ACSF pre-gassed at room
temperature with 95% O2/5% CO2. Neurons in the outer
portion of lamina II of the spinal dorsal horn were visu-
alized using a 40× water immersion objective (Zeiss)
with the aid of differential interference contrast optics
and an infrared-sensitive camera (Newvicon C2400-79,
Hamamatsu). The neurons were used for whole-cell patch-
clamp recordings. Patch pipets with a resistance of 5 MΩ
were filled with a solution containing: KCl 60 mM, KF
65 mM, MgCl2 2 mM, HEPES 10 mM, EGTA 1 mM,
CaCl2 0.1 mM, ATP 2 mM and GTP 0.5 mM at pH =
7.3. The membrane currents or potentials recorded by
the patch-clamp amplifier (Axopatch-200B, Axon In-
struments) were filtered, digitized (Digidata 1200, Axon
Instruments) and stored for later analysis. The series re-
sistance was usually <15 MΩ. The holding potentials,
data acquisition and analysis were controlled by the
software pCLAMP 8.0 (Axon Instruments). Whole-cell
patch-clamp recordings were performed at room
temperature (25°C to 26°C).
In the presence of the GABAA receptor antagonist
picrotoxin (100 μM) and the glycine receptor antagonist
strychnine (5 μM), a concentric bipolar stimulating elec-
trode was placed at the dorsal root entry zone.
Constant-current electrical stimuli (0.2 ms, 1.5 mA to 3
mA, and 0.2 Hz), adequate for high-threshold nocicep-
tive afferent excitation in a rat spinal slice, were used to
evoke monosynaptic glutamatergic excitatory postsynap-
tic currents (EPSCs) [35,36]. The peak amplitudes of ten
consecutive evoked EPSCs in each experiment were av-
eraged at 0.2 Hz. To record spontaneous miniature
EPSCs (mEPSCs), picrotoxin (100 μM), strychnine (5
μM) and the Na+ channel blocker tetrodotoxin (TTX;
0.5 μM) were added to the external solution. Spontan-
eous GABAergic miniature inhibitory postsynaptic cur-
rents (mIPSCs) were recorded in the presence of the
NMDA receptor antagonist 2-amino-5-phosphonovale-
rate (50 μM), the AMPA receptor antagonist 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX; 25 μM), strychnine
(5 μM) and TTX (0.5 μM). The amplitude and frequency
of mEPSCs and mIPSCs were analyzed by the Mini-
Analysis program (Synaptosoft).
Statistics
All results are expressed as the mean ± standard error of
n experiments. Statistical significance among multipleexperimental groups was determined by a one-way
ANOVA followed by a Dunnett’s test. An unpaired Stu-
dent’s t-test (two-tailed) was used to determine whether
there was a significant difference between two groups of
data P < 0.01 was considered significant.
Results
Intrathecal administration of CCL2 induces heat
hyperalgesia
Two-month-old rats were intrathecally administered
with 1 μg of CCL2 dissolved in PBS containing protease
inhibitor cocktail (n = 20). As a control, the vehicle was
intrathecally injected into the animals. Then, the hot
plate test was to verify CCL2-induced thermal hyper-
algesia. Compared to wild-type or vehicle-injected rats
(n = 20), the latency of hind-paw withdrawal caused by
the heat stimulus was significantly reduced 1 day after
the intrathecal injection of CCL2 (Figure 1A). This find-
ing shows that intrathecal administration of CCL2 en-
hances nociceptive transmission in the spinal dorsal
horn and causes heat hyperalgesia.
Intrathecal injection of a potent and specific CCR2 an-
tagonist BMS CCR2 22 (3 μg) [37] did not affect the la-
tency of hind-paw withdrawal in the hot plate test
(Figure 1A; n = 12 animals). However, co-administration
of CCR2 antagonist BMS CCR2 22 (3 μg) with CCL2 (1
μg) completely blocked the CCL2-induced reduction in
the latency of hind-paw withdrawal and thermal hyper-
algesia (Figure 1A; n = 12 animals), indicating that
CCR2 receptors are involved in CCL2-mediated hyper-
algesia in the spinal dorsal horn.
Intrathecal injection of CCL2 strengthens excitatory
glutamatergic transmission by substantia gelatinosa
neurons via a presynaptic mechanism
The augmented excitatory glutamatergic transmission in
substantia gelatinosa (lamina II) neurons could lead to
enhanced nociceptive transmission in the spinal dorsal
horn and resulting hyperalgesia [18,19]. A high level of
CCL2 immunohistochemical staining has been found in
the outer portion of lamina II of the spinal dorsal horn
[2]. Therefore, it was hypothesized that intrathecal injec-
tion of CCL2 causes thermal hyperalgesia by strengthen-
ing glutamatergic transmission in substantia gelatinosa
neurons and facilitating pain transmission in the spinal
dorsal horn. To test this hypothesis, 1 day after intra-
thecally injecting the vehicle or CCL2 (1 μg) into rats,
nociceptive afferent-mediated monosynaptic glutamater-
gic EPSCs, evoked by a stimulating electrode placed at
the dorsal root entry zone, were recorded from outer
lamina II neurons in spinal cord slices prepared from
control vehicle- or CCL2-treated rats (Figure 1B). The
mean resting membrane potential, membrane capaci-
tance and input resistance of control outer lamina II
Figure 1 Intrathecal administration of CCL2 induces heat hyperalgesia and increases the magnitude of evoked glutamatergic EPSCs of
substantia gelatinosa neurons. (A) CCL2 (1 μg) was intrathecally injected into 2-month-old rats. One day after the injection, the hot plate assay
was used to measure hind-paw withdrawal latency. As a control, the vehicle was intrathecally injected into rats. Compared to wild-type (WT) rats
and rats intrathecally administrated with the vehicle, the latency of hind-paw withdrawal caused by the heat stimulus was significantly reduced in
the rats intrathecally injected with CCL2. Note that co-administration of CCR2 antagonist BMS CCR2 22 with CCL2 completely blocked CCL2-induced
thermal hyperalgesia. Each bar shows the mean ± standard error for 12 or 20 rats. *P < 0.01 compared to wild-type rats. (B) One day after intrathecally
injecting the vehicle or CCL2 (1 μg) into the rats, glutamatergic EPSCs were evoked by a stimulating electrode placed at the dorsal root entry zone
and recorded from an outer lamina II neuron in a spinal cord slice prepared from a vehicle- or CCL2-treated rat. Compared to representative EPSCs
evoked by various magnitudes of stimulation currents for control rats, the amplitude of representative EPSCs was significantly higher for lamina
II neurons of CCL2-treated rats. (C) Slope of input–output curve for evoked EPSCs was significantly increased in substantia gelatinosa neurons of
CCL2-injected rats. Each point represents the mean ± standard error for 13 to 15 neurons from seven rats. Holding potential (VH) was -60 mV. *P < 0.01
compared to control neurons.
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23.2 MΩ, respectively (n = 15 neurons from 7 rats).
Intrathecal injection of CCL2 (1 μg) did not significantly
affect the resting membrane potential (-59.4 ± 1 mV;
n = 15 neurons from 7 rats), membrane capacitance
(31.8 ± 1.9 pF) or input resistance (271.8 ± 21.5 MΩ) of
lamina II neurons.
Compared to the evoked glutamatergic EPSCs of outer
lamina II neurons recorded vehicle-treated rats, 1 day
after the intrathecal administration of CCL2 (1 μg), the
amplitude of the evoked EPSCs and the slope of the in-
put–output curve for the evoked EPSCs were signifi-
cantly increased in lamina II neurons of CCL2-treated
rats (Figure 1B,C). These results suggest that intrathecal
injection of CCL2 augments glutamatergic transmission
in substantia gelatinosa neurons and causes the central
sensitization of lamina II neurons.
To determine whether CCL2 enhances glutamatergic
neurotransmission by a presynaptic or postsynaptic
mechanism, we recorded spontaneous glutamatergic
miniature EPSCs (mEPSCs) from lamina II neurons of
control and CCL2-treated rats (Figure 2). One day after
intrathecal administration of CCL2 (1 μg), the frequency
of spontaneous glutamatergic mEPSCs was greatly in-
creased in lamina II neurons from CCL2-treated animals
(Figure 2A,B). Intrathecal injection of CCL2 did not
affect the mean amplitude of mEPSCs (Figure 2A,B).
These results suggest that intrathecal administration of
CCL2 strengthens excitatory glutamatergic transmission
lamina II neurons through a presynaptic mechanism.
We also recorded spontaneous GABAergic mIPSCs
from outer lamina II neurons from vehicle- or CCL2-injected rats. Compared to lamina II neurons from
vehicle-treated animals, intrathecal injection of CCL2
failed to affect the frequency (control frequency was 1.5
± 0.2 Hz; with CCL2, frequency was 1.4 ± 0.1 Hz; n = 7
neurons from 4 rats) or amplitude (control magnitude
was 22.5 ± 2.5 pA; with CCL2, amplitude was 21.8 ± 2.1
pA; n = 7 neurons from 4 animals) of spontaneous
GABAergic mIPSCs in lamina II neurons.
Minocycline inhibits spinal CCL2-induced thermal hyper-
algesia and potentiation of glutamatergic transmission in
substantia gelatinosa neurons
During neuropathic pain, microglial activation plays an
important role in the central sensitization of nociceptive
transmission in the spinal dorsal horn [23-25]. CCL2 is a
key mediator of spinal microglia activation during
neuropathic pain [7,12,23,24,29], and intrathecal injec-
tion of CCL2 induces microglial activation in the spinal
dorsal horn of naive animals [12,32]. Therefore, we hy-
pothesized that intrathecal administration of CCL2
would enhance spinal nociceptive transmission and
cause thermal hyperalgesia by activating the spinal
microglia. This hypothesis was tested using intrathecal
administration of minocycline, a specific inhibitor of
microglial activation [38,39].
Previous studies [40,41] showed that an intrathecal injec-
tion of minocycline (100 μg) blocked microglial activation.
Intrathecal administration of minocycline alone did not
affect the latency of hind-paw withdrawal (Figure 3A). In
accord with our hypothesis that CCL2 causes heat hyper-
algesia by activating the microglia, hot plate assays showed
that intrathecal co-injection of minocycline (100 μg) and
Figure 2 Intrathecal injection of CCL2 strengthens glutamatergic transmission in lamina II neurons via a presynaptic mechanism. (A)
One day after intrathecally injecting vehicle or CCL2 (1 μg) into the rats, spontaneous mEPSCs were recorded from outer lamina II neurons in
spinal cord slices. Compared to a control lamina II neuron, the frequency of spontaneous mEPSCs was significantly increased in a lamina II neuron
from a CCL2-injected rat. VH = -60 mV. (B) Intrathecal administration of CCL2 (1 μg) greatly increased the frequency of mEPSCs in substantia gelatinosa
neurons without affecting the mean amplitude. Each bar shows mean ± standard error for 12 neurons from 6 rats. *P < 0.01 compared to
control neurons. Con, control; mEPSC, miniature excitatory postsynaptic current.
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tion in the latency of hind-paw withdrawal and thermal
hyperalgesia (Figure 3A).
An activated microglia releases pro-inflammatory cyto-
kines, which could alter glutamatergic transmission by
dorsal horn lamina II neurons [30,31]. Thus, it is pos-
sible that CCL2 enhances glutamatergic transmission in
substantia gelatinosa neurons by activating the spinal
microglia. Consistent with this hypothesis, following
intrathecal co-administration of CCL2 (1 μg) and mino-
cycline (100 μg), CCL2 failed to increase the frequency
of glutamatergic mEPSCs and failed to promote glutam-
ine release by outer lamina II neurons (Figure 3B,C).
Intrathecal injection of CCL2 enhances glutamatergic
transmission of substantia gelatinosa neurons and causes
thermal hyperalgesia via TNF-α
In the present study, our results suggest that intrathecal
injection of CCL2 potentiates glutamatergic transmission
in substantia gelatinosa neurons and causes thermal hyper-
algesia by activating the spinal microglia. An activated
microglia releases the pro-inflammatory cytokine tumor
necrosis factor-α (TNF-α) [27-29]. As with the CCL2
effect observed in this study, TNF-α has been shown toincrease the frequency of glutamatergic mEPSCs in lamina
II neurons and enhance excitatory synaptic transmission
in the spinal dorsal horn [30,31]. CCL2 activation of the
spinal microglia is believed to cause the synthesis and
release of TNF-α [7,29]. Therefore, we hypothesized that
intrathecal administration of CCL2 would augment gluta-
matergic transmission by substantia gelatinosa neurons
and cause heat hyperalgesia via TNF-α. This hypothesis
was tested using intrathecal injection of WP9QY, a selective
TNF-α antagonist [42].
Following intrathecal co-administration of CCL2 (1 μg)
and WP9QY (20 μg), CCL2 failed to increase the frequency
of glutamatergic mEPSCs and potentiate glutamatergic
transmission by substantia gelatinosa neurons (Figure
4A,B). Hot plate assays also showed that intrathecal co-
injection of WP9QY (20 μg) and CCL2 (1 μg) completely
blocked CCL2-induced reduction in the latency of hind-
paw withdrawal and thermal hyperalgesia (Figure 4C).
Discussion
Multiple lines of evidence suggest that following a per-
ipheral nerve injury, chemokine CCL2 is involved in me-
diating the hyperalgesia of neuropathic pain in the
dorsal root ganglion (DRG) and spinal dorsal horn
Figure 3 Minocycline inhibits CCL2-induced heat hyperalgesia and blocks CCL2-induced enhancement of glutamatergic transmission in
substantia gelatinosa neurons. (A) Intrathecal administration of CCL2 (1 μg) decreased hind-paw withdrawal latency and caused heat hyperalgesia.
Intrathecal co-injection of minocycline (100 μg) and CCL2 (1 μg) completely blocked the CCL2-induced reduction in the latency of hind-paw
withdrawal and thermal hyperalgesia. Each bar shows mean ± standard error for 10 rats. *P < 0.01 compared to control rats. (B) One day after
intrathecal administration of CCL2 (1 μg), the frequency of spontaneous mEPSCs was greatly increased a lamina II neuron. Intrathecal co-injection
of CCL2 (1 μg) and minocycline (100 μg) inhibited the CCL2-induced increase in the frequency of mEPSCs in a lamina II neuron. VH = -60 mV. (C)
After intrathecal co-administration with minocycline, CCL2 did not significantly increase the frequency of mEPSCs in substantia gelatinosa neurons.
Each bar shows mean ± standard error for 12 neurons from 6 rats. *P < 0.01 compared to control neurons. #P < 0.01 compared to CCL2-treated
neurons. Con, control; mEPSC, miniature excitatory postsynaptic current.
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expression of CCL2 and its receptor CCR2 in the DRG
and spinal dorsal horn [1,3,4,9,10,45-47]. Then, CCL2
induces hyperalgesia by causing peripheral sensitization
of nociceptive DRG neurons and central sensitization of
spinal dorsal horn neurons [6,7,48]. Our previous work
suggested that CCL2 could facilitate pain transmission
mediated by nociceptive DRG neurons and cause hyper-
algesia by upregulating the expression and function of
TRPV1 and Nav1.8 channels in DRG nociceptiveFigure 4 TNF-α antagonist WP9QY blocks CCL2-induced enhancement
and inhibits CCL2-induced heat hyperalgesia. (A) Intrathecal administratio
neuron. Intrathecal co-injection of WP9QY and CCL2 completely inhibited the
VH = -60 mV. (B) After co-administration with WP9QY, CCL2 failed to increase
shows mean ± standard error for 12 neurons from 6 rats. *P < 0.01 compared
Intrathecal injection of CCL2 (1 μg) decreased hind-paw withdrawal latency a
and CCL2 completely inhibited CCL-induced heat hyperalgesia. Each bar repr
rats. Con, control; mEPSC, miniature excitatory postsynaptic current.neurons [49]. The exact mechanism by which CCL2 en-
hances nociceptive transmission in the spinal dorsal
horn and induces the resulting hyperalgesia remains
unknown.
In the present study, behavioral assays indicated that
consistent with a previous study [2], intrathecal adminis-
tration of CCL2 induced thermal hyperalgesia. There-
fore, a rat intrathecally injected with CCL2 is a suitable
animal model for investigating the cellular and molecu-
lar mechanisms by which CCL2 facilitates nociceptiveof excitatory synaptic transmission in substantia gelatinosa neurons
n of CCL2 increased the frequency of spontaneous mEPSCs in a lamina II
CCL2-induced increase in the frequency of mEPSCs in a lamina II neuron.
the frequency of mEPSCs in substantia gelatinosa neurons. Each bar
to control neurons. #P < 0.01 compared to CCL2-treated neurons. (C)
nd caused thermal hyperalgesia. Intrathecal co-administration of WP9QY
esents mean ± standard error for ten rats. *P < 0.01 compared to control
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ing heat hyperalgesia.
The substantia gelatinosa (lamina II) of the spinal dor-
sal horn receives nociceptive information from the per-
ipheral organs through fine myelinated Aδ and
unmyelinated C primary-afferent fibers [13-17]. The vast
majority of substantia gelatinosa neurons are glutamater-
gic excitatory interneurons [50]. Nociceptive information
is integrated by substantia gelatinosa neurons, which
subsequently send a noxious sensation to the somato-
sensory cortex by exciting nociceptive projection neu-
rons in lamina I and lamina V [13-17]. Therefore, the
substantia gelatinosa plays an essential role in processing
nociceptive information and is one of the key sites for
generating central sensitization during neuropathic pain
[18,19]. The excitability and activity of lamina II neurons
arre mainly regulated by glutamate released from pri-
mary nociceptive afferents [14,16,17]. Under pathological
conditions, strengthened glutamatergic transmission and
the resulting augmented excitability of lamina II neurons
could cause the central sensitization of substantia gelati-
nosa neurons, leading to enhanced nociceptive transmis-
sion in the spinal dorsal horn and hyperalgesia [18,19].
After peripheral nerve injury, the central nerve terminals
of DRG neurons and activated astrocytes in the spinal
dorsal horn release CCL2 [3,5]. Immunohistochemical
staining of CCL2 is most intense in the outer portion of
lamina II of the spinal dorsal horn [2]. Therefore, we hy-
pothesized that during neuropathic pain, upregulated
CCL2 in the spinal dorsal horn causes hyperalgesia by
enhancing excitatory glutamatergic transmission in lam-
ina II neurons and facilitating pain transmission in the
spinal dorsal horn. In accord with our hypothesis, intra-
thecal administration of CCL2, which causes thermal
hyperalgesia, increased the magnitude of evoked noci-
ceptive afferent-mediated glutamatergic EPSCs recorded
from outer lamina II neurons.
To determine whether CCL2 augments glutamatergic
neurotransmission by either promoting glutamate re-
lease or potentiating the AMPA receptor-mediated post-
synaptic response, spontaneous glutamatergic mEPSCs
were recorded lamina II neurons of control and CCL2-
treated rats. Intrathecal injection of CCL2 increased the
frequency of spontaneous mEPSCs in lamina II neurons
without affecting the mean amplitude. These results
show that CCL2 facilitates pain transmission in the
spinal dorsal horn and causes heat hyperalgesia by
strengthening excitatory glutamatergic transmission by
substantia gelatinosa neurons via a presynaptic mechan-
ism. Interestingly, a recent study reported that periph-
eral nerve injury upregulated the expression of
chemokine CCL1 in the spinal dorsal horn and that
intrathecal administration of CCL1 induced hyperalgesia
by enhancing glutamatergic neurotransmission in laminaII neurons via a presynaptic mechanism [51]. Therefore,
facilitation of glutamate release and the resulting aug-
mentation of glutamatergic synaptic transmission is
likely to be one of the common pathogenic mechanisms
by which chemokines induce the central sensitization of
substantia gelatinosa neurons and cause neuropathic
hyperalgesia.
Several lines of evidence indicate that microglial activa-
tion in the spinal dorsal horn contributes to the develop-
ment and maintenance of neuropathic pain [7,20-25].
Peripheral nerve injury induces the activation of the micro-
glia in the spinal dorsal horn [20-22]. An intrathecal injec-
tion of activated spinal cord microglia caused thermal
hyperalgesia in naive animals [52]. Inhibition of microglial
activation inhibits the development of neuropathic pain
[26]. Activation of p38 MAPK induced through nerve in-
jury in activated spinal microglia produces via transcrip-
tional regulation various pro-inflammatory cytokines
including TNF-α [27-29]. Pro-inflammatory cytokines re-
leased by activated microglia could cause the central
sensitization of nociceptive dorsal horn neurons by altering
excitatory or inhibitory synaptic transmission, leading to
hyperalgesia [30,31].
Intrathecal administration of CCL2 induces microglial ac-
tivation in the spinal dorsal horn [12,32]. CCL2 activates
p38 MAPK in the microglia of the spinal dorsal horn
[7,29,53]. Intrathecal injection of CCL2-neutralizing anti-
bodies suppressed nerve-injury-induced activation of the
spinal microglia [12,32]. Therefore, CCL2 is an important
mediator of microglia activation in the spinal dorsal horn
during neuropathic pain [7,12,23,24,29]. In the present
study, we hypothesized that intrathecal injection of CCL2
would strengthen glutamatergic transmission by substantia
gelatinosa neurons and cause heat hyperalgesia by inducing
microglial activation. Consistent with our hypothesis, intra-
thecal co-administration of minocycline, a specific inhibitor
of microglial activation, and CCL2 completely blocked
CCL2-induced thermal hyperalgesia and blocked the aug-
mentation of glutamatergic transmission substantia gelati-
nosa neurons. This finding strongly suggests that the
elevation of CCL2 levels induced by peripheral nerve injury
in the spinal dorsal horn causes the central sensitization of
substantia gelatinosa neurons and facilitates spinal nocicep-
tive transmission by activating the spinal microglia.
An activated microglia in the spinal dorsal horn enhances
nociceptive transmission by releasing pro-inflammatory cy-
tokines including TNF-α [27-29]. As with CCL2, intrathecal
injection of TNF-α induces heat hyperalgesia [31]. TNF-α
has also been shown to enhance excitatory synaptic trans-
mission of the spinal dorsal horn by increasing the fre-
quency of spontaneous glutamatergic EPSCs in substantia
gelatinosa neurons [30,31]. Our results indicate that intra-
thecal administration of CCL2 causes thermal hyperalgesia
and increases the frequency of spontaneous glutamatergic
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sion substantia gelatinosa neurons. In the present study,
intrathecal co-administration of WP9QY, a selective TNF-α
antagonist, and CCL2 completely blocked CCL2 augmenta-
tion of glutamatergic transmission in substantia gelatinosa
neurons and CCL2-induced thermal hyperalgesia. There-
fore, it is possible that intrathecal injection of CCL2 acti-
vates spinal microglia and causes the release of TNF-α,
which subsequently augments excitatory glutamatergic
transmission in substantia gelatinosa neurons and mediates
CCL2-induced heat hyperalgesia.
Conclusions
In summary, our results suggest that intrathecal injection
of CCL2 causes thermal hyperalgesia by augmenting excita-
tory glutamatergic transmission in substantia gelatinosa
neurons through a presynaptic mechanism and facilitating
nociceptive transmission in the spinal dorsal horn. Intra-
thecal co-administration of minocycline, a specific inhibitor
of microglial activation, or WP9QY, a selective TNF-α an-
tagonist, completely inhibited CCL2 potentiation of gluta-
matergic transmission substantia in gelatinosa neurons and
CCL2-induced heat hyperalgesia. These results suggest that
upregulation of spinal CCL2 induced by peripheral nerve
injury causes the central sensitization of substantia gelati-
nosa neurons by activating spinal microglia and that TNF-
α mediates CCL2-induced thermal hyperalgesia and aug-
mentation of glutamatergic transmission in lamina II
neurons.
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